Certara, Inc. (CERT)

Market Cap	1.06B -47.0%
Revenue (ttm)	418.84M +8.7%
Net Income	-1.60M
EPS	-0.01
Shares Out	159.14M
PE Ratio	n/a
Forward PE	14.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,271,528
Open	6.58
Previous Close	6.56
Day's Range	6.45 - 6.72
52-Week Range	6.04 - 15.38
Beta	1.58
Analysts	Buy
Price Target	12.22 (+83.76%)
Earnings Date	May 4, 2026

About CERT

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scient...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 1,576
• Stock Exchange: NASDAQ
• Ticker Symbol: CERT
• Website: https://www.certara.com

Financial Performance

In 2025, Certara's revenue was $418.84 million, an increase of 8.75% compared to the previous year's $385.15 million. Losses were -$1.60 million, -86.76% less than in 2024.

Analyst Summary

According to 10 analysts, the average rating for CERT stock is "Buy." The 12-month stock price target is $12.22, which is an increase of 83.76% from the latest price.

Price Target

$12.22

(83.76% upside)

Analyst Consensus: Buy